Determining equivalence and the impact of sample size in anti-infective studies: a point to consider
- 1 January 1996
- journal article
- research article
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 6 (3) , 319-326
- https://doi.org/10.1080/10543409608835146
Abstract
The problem of establishing the equivalence of an experimental treatment to a control with respect to a binary ("success" or "failure") response variable may be solved using an approximate (1-alpha) 100% confidence interval for the difference in the response rates (i.e., success probabilities). If the goal is to show that the experimental treatment is not sufficiently worse than the control, then a decision rule based on the magnitude of one confidence limit can be used. A procedure suggested by the Food and Drug Administration allows the value to which the confidence limit is to be compared to depend on the data. The consequences of determining the sample size assuming that the aforementioned value is fixed are examined. The probability of declaring equivalence and exact sample sizes are also presented for the procedure.Keywords
This publication has 4 references indexed in Scilit:
- Sample Size for Therapeutic Equivalence Based on Confidence IntervalDrug Information Journal, 1995
- Planning and Monitoring of Equivalence StudiesBiometrics, 1990
- Some issues in the design and interpretation of 'negative' clinical studiesArchives of internal medicine (1960), 1986
- Significance Testing to Establish Equivalence between Treatments, with Special Reference to Data in the Form of 2 x 2 TablesBiometrics, 1977